Gestational diabetes & diabetes in pregnancy
Continuous glucose monitoring in the management of gestational diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial
An erratum to this article was published (Lancet Diabetes Endocrinol, Mar 2026 ↗)
Authors' conclusion
Our results show that the outcome in individuals with gestational diabetes is not improved by the use of rtCGM. However, individuals expressed a higher preference for the rtCGM device. This finding suggests that rtCGM could be offered to simplify the management of gestational diabetes. A cost-effectiveness study could address what method requires fewer resources. To our knowledge, this is the first randomised trial powered to evaluate the efficacy of rtCGM regarding pregnancy outcomes.
Study context
- Population
- Pregnant individuals aged 18–45 years with gestational diabetes (IADPSG criteria), university hospital in Bern, Switzerland297 analysed
- Participants
- 302 individuals
- Comparison
- Real-time continuous glucose monitoring (rtCGM) vs self-monitoring of blood glucose (SMBG)
- rtCGMn = 156
- SMBGn = 143reference
- Primary endpoint
- Composite of perinatal outcomes:
- Large for gestational age
- Macrosomia
- Polyhydramnios
- Neonatal hypoglycaemia
- Stillbirth
Methodological detailsopen-label, single-centre
- Open-label
- Single-centre
Primary result
Composite perinatal outcome
Odds ratio
1.02
95% CI 0.63–1.66
As reported in the abstract
Safety
| Outcome | rtCGM | SMBG |
|---|---|---|
| Skin changes (only adverse events)SMBG with blinded device | 4% | <1% |
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →